These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2295217)

  • 1. Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas.
    Schneck D; Butler F; Dugan W; Littrell D; Petersen B; Bowsher R; DeLong A; Dorrbecker S
    Clin Pharmacol Ther; 1990 Jan; 47(1):36-41. PubMed ID: 2295217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
    Spearman ME; Goodwin RM; Kau D
    Drug Metab Dispos; 1987; 15(5):640-7. PubMed ID: 2891480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
    Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
    J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and disposition of the KS1/4 monoclonal antibody-desacetylvinblastine hydrazide conjugate LY203725 in rats and monkeys.
    Lindstrom TD; Althaus WA; Ruterbories KJ; Kau D
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1117-24. PubMed ID: 2319463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.
    Apelgren LD; Zimmerman DL; Briggs SL; Bumol TF
    Cancer Res; 1990 Jun; 50(12):3540-4. PubMed ID: 2340502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructs.
    Apelgren LD; Bailey DL; Briggs SL; Barton RL; Guttman-Carlisle D; Koppel GA; Nichols CL; Scott WL; Lindstrom TD; Baker AL
    Bioconjug Chem; 1993; 4(2):121-6. PubMed ID: 7873643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies.
    Petersen BH; DeHerdt SV; Schneck DW; Bumol TF
    Cancer Res; 1991 May; 51(9):2286-90. PubMed ID: 2015593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.
    Bumol TF; Baker AL; Andrews EL; DeHerdt SV; Briggs SL; Spearman ME; Apelgren LD
    Targeted Diagn Ther; 1988; 1():55-79. PubMed ID: 2979063
    [No Abstract]   [Full Text] [Related]  

  • 9. Solution stability of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB.
    Riggin A; Clodfelter D; Maloney A; Rickard E; Massey E
    Pharm Res; 1991 Oct; 8(10):1264-9. PubMed ID: 1796044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-vinca conjugate: a test of the WLF glass transition theory.
    Roy ML; Pikal MJ; Rickard EC; Maloney AM
    Dev Biol Stand; 1992; 74():323-39; discussion 340. PubMed ID: 1592182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activity.
    Laguzza BC; Nichols CL; Briggs SL; Cullinan GJ; Johnson DA; Starling JJ; Baker AL; Bumol TF; Corvalan JR
    J Med Chem; 1989 Mar; 32(3):548-55. PubMed ID: 2783975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma.
    Elias DJ; Hirschowitz L; Kline LE; Kroener JF; Dillman RO; Walker LE; Robb JA; Timms RM
    Cancer Res; 1990 Jul; 50(13):4154-9. PubMed ID: 2162255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.
    Starling JJ; Maciak RS; Hinson NA; Nichols CL; Briggs SL; Laguzza BC
    Cancer Immunol Immunother; 1989; 28(3):171-8. PubMed ID: 2784353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.
    Trang JM; LoBuglio AF; Wheeler RH; Harvey EB; Sun L; Ghrayeb J; Khazaeli MB
    Pharm Res; 1990 Jun; 7(6):587-92. PubMed ID: 2367327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
    Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
    J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C; Izzo J; Spielmann M; Merle S; May-Levin F; Armand JP; Lacombe D; Tursz T; Sunderland M; Chabot GG
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical pharmacokinetics of vinorelbine (Navelbine).
    Wargin WA; Lucas VS
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma.
    Elias DJ; Kline LE; Robbins BA; Johnson HC; Pekny K; Benz M; Robb JA; Walker LE; Kosty M; Dillman RO
    Am J Respir Crit Care Med; 1994 Oct; 150(4):1114-22. PubMed ID: 7921445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of vinorelbine.
    Levêque D; Jehl F
    Clin Pharmacokinet; 1996 Sep; 31(3):184-97. PubMed ID: 8877249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.